{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "11140916",
  "DateCompleted": {
    "Year": "2001",
    "Month": "03",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "01",
    "Day": "27"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0899-823X",
      "JournalIssue": {
        "Volume": "21",
        "Issue": "12",
        "PubDate": {
          "Year": "2000",
          "Month": "Dec"
        }
      },
      "Title": "Infection control and hospital epidemiology",
      "ISOAbbreviation": "Infect Control Hosp Epidemiol"
    },
    "ArticleTitle": "Choice of antibiotic and risk of colonization with vancomycin-resistant Enterococcus among patients admitted for treatment of community-acquired pneumonia.",
    "Pagination": {
      "StartPage": "789",
      "EndPage": "791",
      "MedlinePgn": "789-91"
    },
    "Abstract": {
      "AbstractText": [
        "A time-series prospective study of patients admitted to the hospital for treatment of community-acquired pneumonia was undertaken to determine vancomycin-resistant enterococcal perianal colonization rates among patients who received ceftriaxone with or without erythromycin versus those who received levofloxacin. A colonization rate of 16% (8/51) was found in the ceftriaxone-erythromycin group versus 0% (0/52) in the levofloxacin group ."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, York Hospital, Pennsylvania 17405, USA."
          }
        ],
        "LastName": "Manzella",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Benenson",
        "ForeName": "R",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pellerin",
        "ForeName": "G",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Kellogg",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Bell",
        "ForeName": "T",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Robertson",
        "ForeName": "M",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Pope",
        "ForeName": "D",
        "Initials": "D"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Infect Control Hosp Epidemiol",
    "NlmUniqueID": "8804099",
    "ISSNLinking": "0899-823X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Bacterial Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Infective Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cephalosporins"
    },
    {
      "RegistryNumber": "63937KV33D",
      "NameOfSubstance": "Erythromycin"
    },
    {
      "RegistryNumber": "6GNT3Y5LMF",
      "NameOfSubstance": "Levofloxacin"
    },
    {
      "RegistryNumber": "75J73V1629",
      "NameOfSubstance": "Ceftriaxone"
    },
    {
      "RegistryNumber": "A4P49JAZ9H",
      "NameOfSubstance": "Ofloxacin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged, 80 and over"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Bacterial Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Infective Agents"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Ceftriaxone"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Cephalosporins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Community-Acquired Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Therapy, Combination"
    },
    {
      "QualifierName": [
        "drug effects",
        "pathogenicity"
      ],
      "DescriptorName": "Enterococcus"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Erythromycin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "drug therapy"
      ],
      "DescriptorName": "Gram-Positive Bacterial Infections"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Levofloxacin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Ofloxacin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pneumonia, Bacterial"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Vancomycin Resistance"
    }
  ]
}